---
document_datetime: 2025-12-02 05:46:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mynzepli.html
document_name: mynzepli.html
version: success
processing_time: 0.0960473
conversion_datetime: 2025-12-26 12:01:17.081065
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mynzepli

[RSS](/en/individual-human-medicine.xml/261745)

##### Authorised

This medicine is authorised for use in the European Union

aflibercept Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Mynzepli](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Mynzepli is a medicine used to treat adults with:

- the 'wet' form of age-related macular degeneration (AMD), a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling;
- impaired vision due to macular oedema (swelling) that follows blockage of either the main vein carrying blood from the retina (known as central retinal vein occlusion, CRVO) or of smaller branch veins (known as branch retinal vein occlusion, BRVO);
- impaired vision due to macular oedema caused by diabetes;
- impaired vision due to choroidal neovascularisation in people with myopia (short-sightedness).

Mynzepli contains the active substance aflibercept and is a biological medicine. It is a 'biosimilar medicine'; this means that Mynzepli is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Mynzepli is Eylea. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines) .

Expand section

Collapse section

## How is Mynzepli used?

Mynzepli can only be obtained with a prescription and must be given by a qualified doctor who is experienced in giving intravitreal injections (injection into the vitreous humour, the jelly-like fluid inside the eye). The medicine is available as a solution for intravitreal injection in vials or prefilled syringes.

Mynzepli is given as an intravitreal injection into the affected eye, repeated as appropriate at intervals of one month or more. How often the injections are given depends on the condition being treated and the response of the patient to treatment.

For more information about how Mynzepli is used, see the package leaflet or contact your doctor or pharmacist.

## How does Mynzepli work?

The active substance in Mynzepli, aflibercept, is an engineered protein that has been designed to attach to and block the effects of a substance called vascular endothelial growth factor A (VEGF-A). It can also attach to other proteins such as placental growth factor (PlGF). VEGF-A and PlGF are involved in stimulating the abnormal growth of blood vessels in patients with AMD, certain types of macular oedema and myopic choroidal neovascularisation. By blocking these factors, aflibercept reduces the growth of abnormal blood vessels and controls leakage and swelling.

## What benefits of Mynzepli have been shown in studies?

Laboratory studies comparing Mynzepli with Eylea have shown that the active substance in Mynzepli is highly similar to that in Eylea in terms of structure, purity and biological activity. Studies have also shown that giving Mynzepli produces similar levels of the active substance in the body to those seen with Eylea.

In addition, a study involving 413 adults with wet AMD found that Mynzepli was as effective as Eylea. In this study, the average number of letters patients could recognise on a standard eye test improved by around 6 letters in both treatment groups after 8 weeks of treatment.

Because Mynzepli is a biosimilar medicine, the studies on the effectiveness of aflibercept carried out with Eylea do not all need to be repeated for Mynzepli.

## What are the risks associated with Mynzepli?

The safety of Mynzepli has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of Eylea.

For the complete list of side effects and restrictions of Mynzepli, see the package leaflet.

The most common side effects with Mynzepli (which may affect more than 1 in 10 people) include conjunctival haemorrhage (bleeding from the small blood vessels on the surface of the eye at the site of injection), retinal haemorrhage (bleeding at the back of the eye), reduced vision and eye pain.

Other common side effects (which may affect up to 1 in 10 people) include vitreous detachment (detachment of the jelly-like substance inside the eye), cataract (clouding of the lens), vitreous floaters (small particles or spots in the vision) and increased intraocular pressure (increased pressure inside the eye).

Some side effects can be serious. Serious injection-related side effects (which have occurred with less than 1 in around 2,000 aflibercept injections in studies) are blindness, endophthalmitis (serious infection or inflammation inside the eye), cataracts, increased intraocular pressure, vitreous haemorrhage (bleeding into the jelly-like fluid in the eye, causing temporary loss of vision) and vitreous or retinal detachment.

Mynzeplimust not be used in patients who have or are thought to have ocular or periocular infections (infections in or around the eyes), or in patients who have severe inflammation inside the eye.

## Why is Mynzepli authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Mynzepli has a highly similar structure, purity and biological activity to Eylea and is distributed in the body in the same way. In addition, a study in adults with wet AMD has shown that Mynzepli and Eylea are equivalent in terms of safety and effectiveness in this condition.

All these data were considered sufficient to conclude that Mynzepli will have the same effects as Eylea in its authorised uses in adults. Therefore, the Agency's view was that, as for Eylea, the benefits of Mynzepli outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Mynzepli?

The company that markets Mynzepli will provide up-to-date educational material for doctors to minimise the risks associated with the injection in the eye and for patients to provide instructions on how to use the medicine, precautions to take and how to recognise serious side effects and know when to seek urgent attention from their doctor.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mynzepli have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Mynzepli are continuously monitored. Suspected side effects reported with Mynzepli are carefully evaluated and any necessary action taken to protect patients.

## Other information about Mynzepli

Mynzepli received a marketing authorisation valid throughout the EU on 18 August 2025.

Mynzepli : EPAR - Medicine overview

Reference Number: EMA/230046/2025

English (EN) (146.48 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/overview/mynzepli-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-224)

български (BG) (173.6 KB - PDF)

**First published:**

17/10/2025

[View](/bg/documents/overview/mynzepli-epar-medicine-overview_bg.pdf)

español (ES) (146.21 KB - PDF)

**First published:**

17/10/2025

[View](/es/documents/overview/mynzepli-epar-medicine-overview_es.pdf)

čeština (CS) (170.99 KB - PDF)

**First published:**

17/10/2025

[View](/cs/documents/overview/mynzepli-epar-medicine-overview_cs.pdf)

dansk (DA) (146.44 KB - PDF)

**First published:**

17/10/2025

[View](/da/documents/overview/mynzepli-epar-medicine-overview_da.pdf)

Deutsch (DE) (149.89 KB - PDF)

**First published:**

17/10/2025

[View](/de/documents/overview/mynzepli-epar-medicine-overview_de.pdf)

eesti keel (ET) (143.32 KB - PDF)

**First published:**

17/10/2025

[View](/et/documents/overview/mynzepli-epar-medicine-overview_et.pdf)

ελληνικά (EL) (173.07 KB - PDF)

**First published:**

17/10/2025

[View](/el/documents/overview/mynzepli-epar-medicine-overview_el.pdf)

français (FR) (149.13 KB - PDF)

**First published:**

17/10/2025

[View](/fr/documents/overview/mynzepli-epar-medicine-overview_fr.pdf)

hrvatski (HR) (169.69 KB - PDF)

**First published:**

17/10/2025

[View](/hr/documents/overview/mynzepli-epar-medicine-overview_hr.pdf)

italiano (IT) (145.2 KB - PDF)

**First published:**

17/10/2025

[View](/it/documents/overview/mynzepli-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (179 KB - PDF)

**First published:**

17/10/2025

[View](/lv/documents/overview/mynzepli-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (168.88 KB - PDF)

**First published:**

17/10/2025

[View](/lt/documents/overview/mynzepli-epar-medicine-overview_lt.pdf)

magyar (HU) (168.16 KB - PDF)

**First published:**

17/10/2025

[View](/hu/documents/overview/mynzepli-epar-medicine-overview_hu.pdf)

Malti (MT) (171.47 KB - PDF)

**First published:**

17/10/2025

[View](/mt/documents/overview/mynzepli-epar-medicine-overview_mt.pdf)

Nederlands (NL) (148.71 KB - PDF)

**First published:**

17/10/2025

[View](/nl/documents/overview/mynzepli-epar-medicine-overview_nl.pdf)

polski (PL) (175.25 KB - PDF)

**First published:**

17/10/2025

[View](/pl/documents/overview/mynzepli-epar-medicine-overview_pl.pdf)

português (PT) (146.71 KB - PDF)

**First published:**

17/10/2025

[View](/pt/documents/overview/mynzepli-epar-medicine-overview_pt.pdf)

română (RO) (164.83 KB - PDF)

**First published:**

17/10/2025

[View](/ro/documents/overview/mynzepli-epar-medicine-overview_ro.pdf)

slovenčina (SK) (170.55 KB - PDF)

**First published:**

17/10/2025

[View](/sk/documents/overview/mynzepli-epar-medicine-overview_sk.pdf)

slovenščina (SL) (166.5 KB - PDF)

**First published:**

17/10/2025

[View](/sl/documents/overview/mynzepli-epar-medicine-overview_sl.pdf)

Suomi (FI) (143.49 KB - PDF)

**First published:**

17/10/2025

[View](/fi/documents/overview/mynzepli-epar-medicine-overview_fi.pdf)

svenska (SV) (144.43 KB - PDF)

**First published:**

17/10/2025

[View](/sv/documents/overview/mynzepli-epar-medicine-overview_sv.pdf)

Mynzepli : EPAR - Risk management plan

English (EN) (1.7 MB - PDF)

**First published:** 17/10/2025

[View](/en/documents/rmp/mynzepli-epar-risk-management-plan_en.pdf)

## Product information

Mynzepli : EPAR - Product information

English (EN) (2.02 MB - PDF)

**First published:** 17/10/2025

[View](/en/documents/product-information/mynzepli-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-224)

български (BG) (2.4 MB - PDF)

**First published:**

17/10/2025

[View](/bg/documents/product-information/mynzepli-epar-product-information_bg.pdf)

español (ES) (1.97 MB - PDF)

**First published:**

17/10/2025

[View](/es/documents/product-information/mynzepli-epar-product-information_es.pdf)

čeština (CS) (2.36 MB - PDF)

**First published:**

17/10/2025

[View](/cs/documents/product-information/mynzepli-epar-product-information_cs.pdf)

dansk (DA) (2.42 MB - PDF)

**First published:**

17/10/2025

[View](/da/documents/product-information/mynzepli-epar-product-information_da.pdf)

Deutsch (DE) (1.91 MB - PDF)

**First published:**

17/10/2025

[View](/de/documents/product-information/mynzepli-epar-product-information_de.pdf)

eesti keel (ET) (1.99 MB - PDF)

**First published:**

17/10/2025

[View](/et/documents/product-information/mynzepli-epar-product-information_et.pdf)

ελληνικά (EL) (2.2 MB - PDF)

**First published:**

17/10/2025

[View](/el/documents/product-information/mynzepli-epar-product-information_el.pdf)

français (FR) (2.44 MB - PDF)

**First published:**

17/10/2025

[View](/fr/documents/product-information/mynzepli-epar-product-information_fr.pdf)

hrvatski (HR) (2.36 MB - PDF)

**First published:**

17/10/2025

[View](/hr/documents/product-information/mynzepli-epar-product-information_hr.pdf)

íslenska (IS) (2.02 MB - PDF)

**First published:**

17/10/2025

[View](/is/documents/product-information/mynzepli-epar-product-information_is.pdf)

italiano (IT) (1.9 MB - PDF)

**First published:**

17/10/2025

[View](/it/documents/product-information/mynzepli-epar-product-information_it.pdf)

latviešu valoda (LV) (1.94 MB - PDF)

**First published:**

17/10/2025

[View](/lv/documents/product-information/mynzepli-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.64 MB - PDF)

**First published:**

17/10/2025

[View](/lt/documents/product-information/mynzepli-epar-product-information_lt.pdf)

magyar (HU) (2.28 MB - PDF)

**First published:**

17/10/2025

[View](/hu/documents/product-information/mynzepli-epar-product-information_hu.pdf)

Malti (MT) (3.42 MB - PDF)

**First published:**

17/10/2025

[View](/mt/documents/product-information/mynzepli-epar-product-information_mt.pdf)

Nederlands (NL) (2.36 MB - PDF)

**First published:**

17/10/2025

[View](/nl/documents/product-information/mynzepli-epar-product-information_nl.pdf)

norsk (NO) (3.09 MB - PDF)

**First published:**

17/10/2025

[View](/no/documents/product-information/mynzepli-epar-product-information_no.pdf)

polski (PL) (3.18 MB - PDF)

**First published:**

17/10/2025

[View](/pl/documents/product-information/mynzepli-epar-product-information_pl.pdf)

português (PT) (3.61 MB - PDF)

**First published:**

17/10/2025

[View](/pt/documents/product-information/mynzepli-epar-product-information_pt.pdf)

română (RO) (3.59 MB - PDF)

**First published:**

17/10/2025

[View](/ro/documents/product-information/mynzepli-epar-product-information_ro.pdf)

slovenčina (SK) (3.15 MB - PDF)

**First published:**

17/10/2025

[View](/sk/documents/product-information/mynzepli-epar-product-information_sk.pdf)

slovenščina (SL) (2.98 MB - PDF)

**First published:**

17/10/2025

[View](/sl/documents/product-information/mynzepli-epar-product-information_sl.pdf)

Suomi (FI) (1.8 MB - PDF)

**First published:**

17/10/2025

[View](/fi/documents/product-information/mynzepli-epar-product-information_fi.pdf)

svenska (SV) (2.96 MB - PDF)

**First published:**

17/10/2025

[View](/sv/documents/product-information/mynzepli-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Mynzepli : EPAR - All authorised presentations

English (EN) (49.25 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-481)

български (BG) (62.98 KB - PDF)

**First published:**

17/10/2025

[View](/bg/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.48 KB - PDF)

**First published:**

17/10/2025

[View](/es/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.69 KB - PDF)

**First published:**

17/10/2025

[View](/cs/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.72 KB - PDF)

**First published:**

17/10/2025

[View](/da/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.44 KB - PDF)

**First published:**

17/10/2025

[View](/de/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.28 KB - PDF)

**First published:**

17/10/2025

[View](/et/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (61.56 KB - PDF)

**First published:**

17/10/2025

[View](/el/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_el.pdf)

français (FR) (47.22 KB - PDF)

**First published:**

17/10/2025

[View](/fr/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (127.7 KB - PDF)

**First published:**

17/10/2025

[View](/hr/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.44 KB - PDF)

**First published:**

17/10/2025

[View](/is/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.97 KB - PDF)

**First published:**

17/10/2025

[View](/it/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (64.99 KB - PDF)

**First published:**

17/10/2025

[View](/lv/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.75 KB - PDF)

**First published:**

17/10/2025

[View](/lt/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (65.41 KB - PDF)

**First published:**

17/10/2025

[View](/hu/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.06 KB - PDF)

**First published:**

17/10/2025

[View](/mt/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.36 KB - PDF)

**First published:**

17/10/2025

[View](/nl/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.42 KB - PDF)

**First published:**

17/10/2025

[View](/no/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_no.pdf)

polski (PL) (68.08 KB - PDF)

**First published:**

17/10/2025

[View](/pl/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.08 KB - PDF)

**First published:**

17/10/2025

[View](/pt/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_pt.pdf)

română (RO) (62.04 KB - PDF)

**First published:**

17/10/2025

[View](/ro/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.67 KB - PDF)

**First published:**

17/10/2025

[View](/sk/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.46 KB - PDF)

**First published:**

17/10/2025

[View](/sl/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.51 KB - PDF)

**First published:**

17/10/2025

[View](/fi/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.45 KB - PDF)

**First published:**

17/10/2025

[View](/sv/documents/all-authorised-presentations/mynzepli-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Mynzepli Active substance aflibercept International non-proprietary name (INN) or common name aflibercept Therapeutic area (MeSH)

- Wet Macular Degeneration
- Macular Edema
- Diabetes Complications
- Retinal Vein Occlusion
- Choroidal Neovascularization

Anatomical therapeutic chemical (ATC) code S01LA05

### Pharmacotherapeutic group

Ophthalmologicals

### Therapeutic indication

Mynzepli is indicated for adults for the treatment of - neovascular (wet) age-related macular degeneration (AMD), - visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), - visual impairment due to diabetic macular oedema (DME), - visual impairment due to myopic choroidal neovascularisation (myopic CNV)

## Authorisation details

EMA product number EMEA/H/C/006438

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Advanz Pharma Limited

Unit 17 Northwood House Northwood Crescent Dublin 9 D09 V504 Ireland

Opinion adopted 19/06/2025 Marketing authorisation issued 18/08/2025

## Assessment history

## Initial marketing authorisation documents

Mynzepli : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/203339/2025

English (EN) (4.81 MB - PDF)

**First published:** 17/10/2025

[View](/en/documents/assessment-report/mynzepli-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Mynzepli

Adopted

Reference Number: EMA/202775/2025

English (EN) (149.26 KB - PDF)

**First published:** 20/06/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-mynzepli_en.pdf)

#### News on Mynzepli

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 June 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-june-2025) 20/06/2025

**This page was last updated on** 17/10/2025

## Share this page

[Back to top](#main-content)